Vimarsana
Biggest News Aggregation in the World

Exome Sequencing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exome Sequencing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exome Sequencing Today - Breaking & Trending Today

First Study Using Biomimetic AI Digital Twins and Multiomics in Genetics Research - Vimarsana News

First Study Using Biomimetic AI Digital Twins and Multiomics in Genetics Research

Published: April 11, 2024

BioPharma

Source: biopharmadive.com
Related Topics:
Raymond Anchan BrighamAndrew BennerMaya SeshanLaura Kearns GenzevaJ Georgios StamoulisBradford Wilson IndygeneLawrence BaischRay AnchanJoseph GlickPeter FiorilloWilliamg KearnsBrigham Women Hospital Of Harvard UniversityProfessor Harvard Medical School CoWomen Hospital CenterHarvard UniversityMolecular DiagnosticsChief Scientific OfficerDigital Twin EcosystemKnowledge EngineeringBiomimetic Digital Twin EcosystemPhenotype Driven Variant AnalysisExome SequencingMolecular MechanismsDalton BroughBradford Wilson
Exome sequencing unravels complex genetic diagnoses in growth disorders - Vimarsana News

Exome sequencing unravels complex genetic diagnoses in growth disorders

Published: February 17, 2024

In an article published in the Journal of Pediatrics, researchers based in Brazil describe the case of a nine-year-old boy admitted to hospital with multiple symptoms and overlapping conditions that made diagnosis difficult, such as short stature, thin tooth enamel (dental enamel hypoplasia), moderate mental deficiency, speech delay, asthma, mildly altered blood sugar, and a history of recurring infections in infancy.

Source: news-medical.net
Related Topics:
Paulo Medical SchoolPaulo Research FoundationMedical SchoolAugusto De Lima JorgeLima JorgeBlood SugarExome SequencingMedical SchoolT CellTooth EnamelWhole Genome Sequencing
Whole Exome Sequencing Global Market Report 2024: Projected - Vimarsana News

Whole Exome Sequencing Global Market Report 2024: Projected

Published: January 25, 2024

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The

Source: globenewswire.com
Related Topics:
United StatesClinicient IncFoundation Medicine IncGenedx IncAgilent TechnologiesPersonalis IncThermo Fisher Scientific IncRoche LtdArcherdx IncGeneyx Genomex LtdPerkinelmer IncFulgent Genetics IncPsomagen IncNatera IncAzenta Us IncMacrogen IncBioneer CorporationOtogenetics CorporationNovogene CorporationBionano Genomics IncBio Rad Laboratories IncIllumina IncExome Sequencing Global Market ReportPersonalized MedicineDiagnostic Techniques
New diagnostic workflow improves detection of 5q-spinal muscular atrophy - Vimarsana News

New diagnostic workflow improves detection of 5q-spinal muscular atrophy

Published: November 15, 2023

5q-spinal muscular atrophy (5q-SMA) is one of the more common types of spinal muscular atrophy (SMA) affecting around one in ten thousand individuals worldwide.

Source: news-medical.net
Related Topics:
Teresa NeuhannAngela AbichtDepartment Of NeurologyGenetics CenterLead InvestigatorMedical Genetics CenterHuman Phenotype OntologyMuscular AtrophySpinal Muscular AtrophyExome Sequencing
PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE - Vimarsana News

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

Published: November 13, 2023

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate hasdemonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] PKD is a life-changing disease affecting 1 in every 1,000 people[3] Half of the patient population withPKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4] PKD represents an addressable market of >US$10 billion p.a. and is an area of major commercial interest for the ...

Source: singaporestar.com
Related Topics:
Western AustraliaCrown BiosciencesHuman Genetics ResearchDrug AdministrationPolycystic Kidney DiseaseWebinar FridayAutosomal Dominant Polycystic Kidney DiseaseInvestigational New DrugNew Drug ApplicationDrug DiscoveryExome SequencingUnited Kingdom BiobankPyc Has Developeda New Drug Candidate For The Gt 5 Million People Worldwide 1 With Polycystic Kidney Disease Pkd This Hasdemonstrated Efficacy In Human Models Derived From Kidneys Of Patients End Stage Renal Failure Due To 2 Isa Life Changing Affecting Every000 People 3 Half Of The Patient Population Withpkd Will Requirea Kidney Transplant By Age 60 Due To Absence Impactful Treatment Options In This Disease 4 Pkd Represents An Addressable Market Gt Us 10 Billion Pa And Is Area Major Commercial Interest For Drug Development Industry 5 Pre Clinical Models Suggest That Addressing Underlying Cause Ofpkd Way Pyc 39s Candidate Works Could Arrest Course HumansNabling Damaged Kidneys To Regenerate And Restore Function 6 Pyc Plans Accelerate This Drug Candidate Into Human Trials In 12 Months Pursuinga Potential High Velocity Path Through Clinical Market 7 Investor Webinar Friday 17 November Will Host An Call At 9am Awst 12pm Aedst On Discuss These Results Investors Can Register For The Here Https Us02web Zoom Us Wn P2qqkkz Txoms2moaujijg PerthUstralia And San FranciscoNov 13023 Prnewswire Pyctherapeutics Today Announces The Results Ofa Study Conducted In Human 3 Dimensional Models Derived From Patients With End Stage Renal Failure Due To Autosomal Dominant Polycystic Kidney Disease Pkd Demonstrate That An Investigational Drug Candidate Designed By Pyc Known As 003 Address This At Its Root Cause Is Effective These 3d Patient Cyst Represent 39 Gold Standard Pre Clinical Assay For Evaluating Candidates Indication 8 Fourth Program Company 39s Development Pipeline Joining Three Other First Class Rna Modifying Potential Currently Progressing Into Or Through Trials Figure 1 Reduction Size And Frequency Following Treatment Ina Model Generated Using Tissue Collected Directly Kidneys Of 9 Shows Larger Cysts Stained Blue Red Untreated When Compared Treated 2 Quantification Area Control 5 H2o Labelled Mock 10 Next Steps Plans Accelerate New Ind Application Us Food Administration Fda Enable Commencement Planned H2 2024 Expected Have Accelerated Pathway Extent Unmet Need Pkda Support Could Be Submitted Two Rather Than Conventional 11 Isa Monogenic Meaning It Caused Bya Mutation Single Gene Drugs Targeting Diseases Highest Likelihood Demonstrating Efficacy 12 Lower Probability Off Target Safety Issues Representsa Major Global Health Challenge Affects Every000 People Across The Globe There Are Currently No Drugs Available That Address Underlying Cause Of Disease And Approximately 50 Pkd Patients Will Progress To End Stage Renal Failure By Age 60 Is Characterised Formation Multiple Fluid Filled Cysts Throughout KidneyOa Lesser ExtentTher Organs Progression Of The Cyst Frequency And Volume Over Time Ultimately Leads To Destruction Internal Architecture Function Kidney Figure 3 An Illustration Impact Pkd On 13 Increase In Size Abnormal Appearance Is Driven By Formation Swelling That Characterises Disease Compromises Pyc Has Solved 39 Other Critical Dimension Delivery Challenge Data Demonstrating 003 Effective 3d Patient Derived Models Complements Existing From Animal Highlighting Ability This Drug Candidate Reach Cells Affected 14 39s Platform Already Demonstrated Deliver Rna Therapy Target Vivo High Concentration See 4 Cross Section Ofa Mouse Days Aftera Single 10mg Kg Intravenous Dose Equivalent Illustrated With Pink Dots Mirnascope Within Organ Investor Call Will Host Friday 17 November At 9am Awst 12pm Aedst Explain Program Detail Investors Can Register For Following Link Https Us02web Zoom Us Webinar Wn P2qqkkz Txoms2moaujijg About Therapeutics Asx Isa Clinical Stage Biotechnology Company Creatinga New Generation Therapies Change Lives Patients Genetic Diseases Utilises Its Proprietary Enhance Potency Precision Medicines Rapidly Growing Commercially Proven Therapeutic Class Development Programs Monogenic Indications Highest Likelihood Success 15 Was First Progressa Fora Blinding Eye Childhood Into Human Trials Now Progressing Multiple Fast Follower Clinic More InformationIsit Pyctx ComR Follow Us On Linkedinand Twitter Forward Looking Statements Any In This Asx Announcement Have Been Prepared The Basis Ofa Number Of Assumptions Which May Prove Incorrect And Current IntentionsNd Beliefs About Future Events Are Subject To RisksNcertainties And Other Factors